Schall Thomas J.

Director Schall Thomas J. purchases 21,645 shares of IMRX at $4.67; stock down 48.4% from 52-week high amid unprofitable operations.

Director Thomas J. Schall purchased 21,645 shares at $4.67 on 2026-01-15, increasing his holdings by 40.9% to 74,530 shares. This buy occurs while the stock trades 48.4% below its 52-week high of $9.26 and has declined 15.4% in the past 30 days. The company reported zero revenue in the latest quarter and a net loss of $14,964,875.00 for the full fiscal year, with annual revenue down 100.0%. On his cross-ticker track record, Schall's prior 3 buys averaged 90-day returns of +110.1% with a 66.67% win rate; however, his same-ticker history at IMRX shows mixed timing—2 of 3 prior buys were well-timed at the 90-day mark, while one incurred a -44.6% loss. A cluster of 4 other insiders also bought within the past 14 days, indicating coordinated insider buying activity despite the company's deteriorating financial position and recent price weakness.

Director Schall purchased 9,500 shares of IMRX at $3.66 on 2025-06-27; 4 other insiders also bought within 14 days.

Thomas J. Schall, a director at Immuneering Corp, purchased 9,500 shares at $3.66, increasing his holdings by 21.9% to 52.9K shares. This transaction occurred amid a broader cluster pattern, with 4 other insiders also buying within the past 14 days. However, the insider's cross-ticker track record is concerning: across 2 prior open-market purchases at other companies, his average 90-day return was -44.6% with a 0.00% win rate. At IMRX specifically, a prior purchase on 2024-03-22 also declined 44.6% over 90 days. Immuneering is unprofitable with net income of $-15.0M and revenue of $0.00 in the latest quarter, substantially down from prior year.

Director Schall bought 40,485 shares of IMRX at $2.21; holdings grew 1396.0% to 43,385 shares amid cluster pattern.

Thomas J. Schall, a director, purchased 40,485 shares at $2.21 on 2025-06-17, increasing his holdings from 2,900 shares to 43,385 shares—a 1396.0% increase. The stock has recovered 82.2% over the past 30 days and 67.9% over 90 days, trading at $2.77 currently and well below its 52-week high of $3.21. However, Schall's prior buy at IMRX in March 2024 produced a 90-day return of -44.6%, establishing a 0.00% win rate on his sole prior purchase at this ticker. Against broader cross-ticker history, his aggregate buy timing shows 0.00% success with an average 90-day return of -44.6%. The purchase coincides with a cluster of 2 other insider buys within the past 14 days, but the company remains deeply unprofitable (net income of -$15,046,132.00) with zero quarterly revenue and -100.0% annual revenue growth, raising questions about the durability of recent price strength.